Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
Last trade$16.27
Day change+$0.11 (+0.68%)
Day range$15.63 – $16.45
Volume257,748
Market cap$902M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$901.69M
Price / earnings
—
Price / book
1.97×
Price / sales
74.55×
EV / sales
68.9×
EV / EBITDA
-8.21×
Profitability
Earnings per share
-$1.58
Return on assets
-16.52%
Return on equity
-19.16%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
14.22×
Quick ratio
14.22×
Cash ratio
1.94×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$91.99M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AKTS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Revenue
$3.91M
$3.38M
$3.23M
Cost of revenue
$0
$0
$0
Gross profit
$3.91M
$3.38M
$3.23M
Selling, general and administrative
$6.53M
$7M
$5.9M
Research and development
$32.13M
$25.28M
$20.04M
Total operating expenses
$38.65M
$32.28M
$25.93M
Operating income
-$34.75M
-$28.9M
-$22.71M
Interest expense
$0
$0
$0
Income before taxes
-$29.94M
-$24.14M
-$18.33M
Income taxes
$0
$0
$0
Net income
-$29.94M
-$24.14M
-$18.33M
Net income attributable to common shareholders
-$29.94M
-$24.14M
-$18.33M
EBITDA
-$33.81M
-$28.02M
-$22.05M
Basic earnings per share
-$0.54
-$0.44
-$0.38
Diluted earnings per share
-$0.54
-$0.44
-$0.38
Recent news
Company coverage with links to the original publishers.
Aktis (AKTS) stock has gained 4.9% over the past four weeks and closed at $17.45. Wall Street analysts have set a mean price target of $35.88, suggesting a potential upside of 105.6%. The stock has a Zacks Rank #2 (Buy) rating, and analysts have shown increasing optimism with positive earnings estimate revisions, though the article cautions that price targets should not be the sole basis for investment decisions.
Avidity Partners Management initiated a new $9.1 million position in Aktis Oncology (AKTS) during Q1 2026, acquiring 468,566 shares. The clinical-stage biotech company develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform. With a strong balance sheet of $538.5 million in cash and clinical trials underway, Avidity's investment signals confidence in Aktis' potential as an emerging oncology player, though the company remains early in development.
Aktis Oncology announced that its President and CEO Matthew Roden will present at the BofA Securities Health Care Conference on May 13, 2026. The company is advancing its miniprotein radioconjugate platform for targeted radiopharmaceuticals, with lead programs AKY-1189 targeting Nectin-4 and AKY-2519 targeting B7-H3 across multiple solid tumor indications.
Aktis Oncology announced that clinical imaging and dosimetry data for AKY-2519, a miniprotein radioconjugate targeting B7-H3, will be presented in two poster presentations at the 2026 ASCO Annual Meeting in May. The FDA cleared IND applications for AKY-2519 in March 2026, enabling the company to proceed with a Phase 1b clinical trial starting mid-2026. AKY-2519 is the company's second clinical-stage miniprotein radioconjugate, following its lead program AKY-1189 targeting Nectin-4.
Aktis Oncology, a radiopharmaceutical biotech company, went public on January 9, 2026, raising $318 million in one of the largest recent biotech IPOs. The company specializes in targeted alpha radiopharmaceuticals for cancer treatment. With backing from Eli Lilly (which invested $100 million in shares), a growing nuclear medicine market projected to reach $35 billion by 2030, and an experienced management team, the stock may appeal to long-term investors despite being pre-revenue.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.